+Compare
VINC
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
14.47M

VINC Vincerx Pharma Forecast, Technical & Fundamental Analysis

a blank check company, which was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, and reorganization

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for VINC with price predictions
07:00 PM EST Dec 04, 2023

VINC in downward trend: 10-day moving average moved below 50-day moving average on November 10, 2023

The 10-day moving average for VINC crossed bearishly below the 50-day moving average on November 10, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

VINC moved below its 50-day moving average on November 07, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VINC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for VINC entered a downward trend on December 05, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VINC's RSI Indicator exited the oversold zone, of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 40 cases where VINC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where VINC advanced for three days, in of 166 cases, the price rose further within the following month. The odds of a continued upward trend are .

VINC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.870) is normal, around the industry mean (20.694). P/E Ratio (0.000) is within average values for comparable stocks, (137.286). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.913).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. VINC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VINC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 12%. For the same Industry, the average monthly price growth was 25%, and the average quarterly price growth was 27%. CMND experienced the highest price growth at 3,849%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was 81%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 59
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

VINC is expected to report earnings to fall 21.74% to -36 cents per share on March 26

Vincerx Pharma VINC Stock Earnings Reports
Q4'23
Est.
$-0.36
Q3'23
Est.
$-0.46
Q2'23
Beat
by $0.08
Q1'23
Missed
by $0.44
Q4'22
Missed
by $0.15
The last earnings report on November 14 showed earnings per share of -46 cents, missing the estimate of -45 cents. With 22.67K shares outstanding, the current market capitalization sits at 14.47M.
A.I. Advisor
published General Information

General Information

a blank check company, which was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, and reorganization

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
260 Sheridan Avenue
Phone
+1 650 800-6676
Employees
41
Web
https://www.vincerx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HARP10.620.38
+3.71%
Harpoon Therapeutics
ZGN12.100.25
+2.11%
Ermenegildo Zegna NV
NVR6359.08-28.97
-0.45%
NVR
UAN67.01-1.20
-1.76%
CVR Partners LP
IINN1.06-0.04
-3.20%
Inspira Technologies Oxy BHN Ltd

VINC and

Correlation & Price change

A.I.dvisor indicates that over the last year, VINC has been loosely correlated with APVO. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if VINC jumps, then APVO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VINC
1D Price
Change %
VINC100%
+0.03%
APVO - VINC
33%
Loosely correlated
+0.15%
HARP - VINC
33%
Poorly correlated
+3.71%
AFMD - VINC
32%
Poorly correlated
-1.53%
RNA - VINC
31%
Poorly correlated
-3.86%
VNDA - VINC
30%
Poorly correlated
+2.86%
More

Groups containing VINC

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VINC
1D Price
Change %
VINC100%
+0.03%
capital stock exchange
(undefined stocks)
7%
Poorly correlated
-1.37%
check company
(undefined stocks)
7%
Poorly correlated
-1.14%
blank
(undefined stocks)
7%
Poorly correlated
-1.14%
asset acquisition
(undefined stocks)
6%
Poorly correlated
-0.58%
merger
(undefined stocks)
6%
Poorly correlated
-0.58%
More